UNSPSC 51172167: Dexsecoverine hydrochloride

This classification denotes the hydrochloride form of an antispasmotic agent and antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3O6AUX3I0J. European Medicines Agency schedules Dexsecoverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07047MIG. Dexsecoverine generally arises in the molecular formula C22H35NO2.

UNSPSC 51172167 Dexsecoverine hydrochloride is a Commodity code that captures pharmaceutical products used in drug testing and specimen collection services purchased by state and local criminal justice, health, and employee benefit agencies. State and local governments buy this product—and related pharmaceutical testing reagents—as part of offender drug screening, workplace drug testing compliance programs, and therapeutic pharmacy initiatives. The issuing bodies include county probation and community supervision departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple states.

Recent activity centers on Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 over two years plus optional renewals; the scope includes immunoassay screening and LC/MS/MS or GC/MS confirmation across collection sites in Plano and McKinney, with approximately 25,031 annual tests comprising five- and six-panel screens and ancillary testing. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory procurement to inform future pharmacy benefit contracting. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon; awarded vendors must maintain relationships with AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, and comply with cGMP and Drug Supply Chain Security Act requirements, with contract effective July 1, 2026.